The discovery of specific gene mutations, termed "driver mutations", in different tumors has brought personalized medicine into the focus of cancer treatment. Targeted treatment agents generally are administered orally and have a tolerable adverse event profile; they have become widely used in both inpatient and outpatient settings. The approval of the selective BRAF inhibitor vemurafenib (Zelboraf®) as first-line therapy of metastatic melanoma in Europe in February 2012 as well as the increasing use of MEK inhibitors within clinical trials confronts dermatologists and oncologists with a new spectrum of side effects. Knowledge of these possible adverse events and their management will be crucial for optimized patient care. This article offers an overview of the most important adverse events of currently employed dermato-oncologic therapeutic agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1610-0387.2012.07942.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing Environmental Justice in Mexico: How Polluting Industries and Healthcare Disparities Impact Congenital Heart Defects.
Birth Defects Res
March 2025
Neurometabolic Translational Research Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Background: Congenital heart defects (CHDs) are the most prevalent birth defects globally and the second leading cause of death in Mexican children under five. This study examines how industrial activity and social vulnerabilities independently and jointly influence CHD incidence across 2446 Mexican municipalities from 2008 to 2019.
Methods: Using negative binomial regression models, we evaluated associations between polluting industries, healthcare access, and CHD incidence.
Medication experiences in the treatment of opioid use disorders: Insights from Reddit.
Addiction
March 2025
Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA.
Background And Aims: Better understanding the challenges faced by patients on medications for opioid use disorder (MOUD), including methadone and buprenorphine, is critical to increasing their use/retention. Social media platforms such as Reddit offer a space for patients to share their experiences with medications. We aimed to identify and characterize challenges faced by patients taking MOUD through analysis of discussions from the r/Methadone and r/suboxone subreddits.
View Article and Find Full Text PDFTesting syndemic models along pathways to psychotic spectrum disorder: implications for population-level preventive interventions.
Psychol Med
March 2025
Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Background: Population-level preventive interventions are urgently needed and may be effective for psychosis due to social determinants. We tested three syndemic models along pathways from childhood adversity (CA) to psychotic spectrum disorder (PSD) and their implications for prevention.
Methods: Cross-sectional data from 7461 British men surveyed in 5 population subgroups.
p16INK4a Deletion Alleviated Obesity-Associated Kidney Fibrosis by Regulating Metabolic Reprogramming and the Inflammasome Pathway.
J Cell Mol Med
March 2025
Department of Cardiology, The Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.
Recent research has revealed a close association between obesity and various metabolic disorders, including renal metabolic diseases, but the mechanism is still unknown. This study explored the role of p16INK4a in obesity-related kidney fibrosis and evaluated its potential as a therapeutic target. Using wild-type (WT) mice and p16 KO mice, we fed both groups a high-fat diet (HFD) for 6 months.
View Article and Find Full Text PDFOpioid withdrawal syndrome induced by naldemedine administration in a cancer patient without brain metastasis.
Palliat Support Care
March 2025
Departments of Psycho-oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Objectives: Naldemedine is a peripherally acting μ-opioid receptor antagonist used to treat opioid-induced constipation. As this drug does not cross the blood-brain barrier, it is believed that patients without brain metastases do not experience opioid withdrawal symptoms.
Methods: Here, we experienced a case in which a cancer patient without brain metastasis presented with anxiety and restlessness that was severe enough to interfere with daily life.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!